GSK'S Nelarabine costs USD33,600 per month, putting undue financial burden on cancer patients
Over 800 Mn people spend a minimum of 10% of their household budget on healthcare, and 100 Mn people end up in extreme poverty due to unaffordable out-of-pocket (OOP costs) health expenses1. Blood cancer care is expensive to the healthcare system. In the first year following the patient's diagnosis, the average annual allowed spending for treating blood cancer is $156,000, and the high expenses continue beyond the first year 3:p2. About 12% of cancer patients lowered the dose of prescription drugs to make them last longer7. Leukemia & Lymphoma are the most common blood cancer4, accounting for over one million new cases and 573,725 deaths worldwide in 20202.
GSK, 10 billion pills donated (and counting) to address neglected diseases.
Nearly 30% of the world's population (2 bn people) lack access to basic healthcare services1. Further, impacted people are predominantly living in low and middle-income countries where demographic growth is the strongest2;p.1, thus increasing the scale of the challenge.
Guided by its female CEO, GSK is the right way to eradicate gender inequality in its workforce.
Women accounted for 70% of the world's total health care workers in 20191;p3. Women tend to be part-time employees more likely than men. Globally, in health care, the pay gap between men and women was 11.2% in 20191;p3. The Inclusion of women in healthcare is more important because women make up 80% of decision-makers in using medicines at home3.
GlaxoSmithKline donated USD 360 Mn in 2019 for community health programs
According to the World Health Organisation approximately 2 Bn people lack access to basic medicines1. About 80% of the global population lives in countries where access to controlled medicines that are used for relieving moderate pains is zero or minute2;p15. Worldwide, about 100 Mn people end up in extreme poverty due to out of pocket health expenses3.
GlaxoSmithKline discharged 9.9 Mn m3 of wastewater in FY2019
The UN has stated that 80% of global discharged wastewater returns into the environment without being properly treated2. In the pharmaceutical industry, approximately half of the wastewater produced is discharged without proper treatment1. A major wastewater source in the pharmaceutical industry comes from washing and cleaning equipment in various manufacturing plants after each batch of medicines3;p4.